Tags

Type your tag names separated by a space and hit enter

Selective inhibition of [D-Ala2, Glu4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor.
Life Sci. 1994; 55(2):PL37-43.LS

Abstract

Evidence in vivo has suggested the existence of subtypes of the delta opioid receptor (DOR), which have been termed delta 1 and delta 2. These proposed DOR subtypes are thought to be activated by [D-Pen2, D-Pen5]enkephalin (DPDPE, delta 1) and [D-Ala2, Glu4]deltorphin (delta 2). Recent work in which an antisense oligodeoxynucleotide (oligo) to a cloned DOR was administered by the intrathecal (i.th.) route has demonstrated a reduction in the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4]deltorphin, but not of [D-Ala2, NMPhe4, Gly-ol]enkephalin (DAMGO, mu agonist) in mice. The present investigation has extended these observations by administering the same DOR antisense oligo sequence by the intracerebroventricular (i.c.v.) route and evaluating the antinociceptive actions of i.c.v. agonists selective for delta, mu and kappa receptors. I.th. treatment with DOR antisense oligo, but not mismatch oligo, significantly inhibited the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4]deltorphin but not of i.th. DAMGO or U69,593 (kappa agonist), confirming previous data. In contrast, i.c.v. DOR antisense oligo, but not mismatch oligo, selectively inhibited the antinociceptive response to i.c.v. [D-Ala2, Glu4]deltorphin without altering the antinociceptive actions of i.c.v. DPDPE, DAMGO or U69,593. The data suggest that the cloned DOR corresponds to that pharmacologically classified as delta 2 and further, suggest that this delta receptor subtype may play a major role in eliciting spinal delta-mediated antinociception.

Authors+Show Affiliations

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson 85724.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8015351

Citation

Bilsky, E J., et al. "Selective Inhibition of [D-Ala2, Glu4]deltorphin Antinociception By Supraspinal, but Not Spinal, Administration of an Antisense Oligodeoxynucleotide to an Opioid Delta Receptor." Life Sciences, vol. 55, no. 2, 1994, pp. PL37-43.
Bilsky EJ, Bernstein RN, Pasternak GW, et al. Selective inhibition of [D-Ala2, Glu4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sci. 1994;55(2):PL37-43.
Bilsky, E. J., Bernstein, R. N., Pasternak, G. W., Hruby, V. J., Patel, D., Porreca, F., & Lai, J. (1994). Selective inhibition of [D-Ala2, Glu4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. Life Sciences, 55(2), PL37-43.
Bilsky EJ, et al. Selective Inhibition of [D-Ala2, Glu4]deltorphin Antinociception By Supraspinal, but Not Spinal, Administration of an Antisense Oligodeoxynucleotide to an Opioid Delta Receptor. Life Sci. 1994;55(2):PL37-43. PubMed PMID: 8015351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selective inhibition of [D-Ala2, Glu4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor. AU - Bilsky,E J, AU - Bernstein,R N, AU - Pasternak,G W, AU - Hruby,V J, AU - Patel,D, AU - Porreca,F, AU - Lai,J, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - PL37 EP - 43 JF - Life sciences JO - Life Sci VL - 55 IS - 2 N2 - Evidence in vivo has suggested the existence of subtypes of the delta opioid receptor (DOR), which have been termed delta 1 and delta 2. These proposed DOR subtypes are thought to be activated by [D-Pen2, D-Pen5]enkephalin (DPDPE, delta 1) and [D-Ala2, Glu4]deltorphin (delta 2). Recent work in which an antisense oligodeoxynucleotide (oligo) to a cloned DOR was administered by the intrathecal (i.th.) route has demonstrated a reduction in the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4]deltorphin, but not of [D-Ala2, NMPhe4, Gly-ol]enkephalin (DAMGO, mu agonist) in mice. The present investigation has extended these observations by administering the same DOR antisense oligo sequence by the intracerebroventricular (i.c.v.) route and evaluating the antinociceptive actions of i.c.v. agonists selective for delta, mu and kappa receptors. I.th. treatment with DOR antisense oligo, but not mismatch oligo, significantly inhibited the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4]deltorphin but not of i.th. DAMGO or U69,593 (kappa agonist), confirming previous data. In contrast, i.c.v. DOR antisense oligo, but not mismatch oligo, selectively inhibited the antinociceptive response to i.c.v. [D-Ala2, Glu4]deltorphin without altering the antinociceptive actions of i.c.v. DPDPE, DAMGO or U69,593. The data suggest that the cloned DOR corresponds to that pharmacologically classified as delta 2 and further, suggest that this delta receptor subtype may play a major role in eliciting spinal delta-mediated antinociception. SN - 0024-3205 UR - https://www.unboundmedicine.com/medline/citation/8015351/Selective_inhibition_of_[D_Ala2_Glu4]deltorphin_antinociception_by_supraspinal_but_not_spinal_administration_of_an_antisense_oligodeoxynucleotide_to_an_opioid_delta_receptor_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0024-3205(94)90110-4 DB - PRIME DP - Unbound Medicine ER -